People with overweight or obesity who used tirzepatide lost about 7% more weight during the year after beginning treatment compared with those who used semaglutide, a recent observational study published in JAMA Internal Medicine found. However, the majority of people in both groups had lost 5% or more of their original body weight within 1 year of starting treatment.
